Clinical trials: Mental Disorder in Adolescence
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
The purpose of this study is to provide information regarding the relative effectiveness of three different atomoxetine doses in the treatment of Korean children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)
- Trial name
- NCT00568685
- Testing
- Atomoxetine Hydrochloride
- Where
- 3 sites in South Korea
- Volunteers
- 153 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
A Study of Atomoxetine for Attention Deficit and Hyperactive/Impulsive Behaviour Problems in Children With ASD
The primary purpose of this study is to evaluate the tolerability and effectiveness of atomoxetine in the treatment of attention problems, hyperactivity, and impulsivity in children with ASD, and secondarily, to evaluate the…
- Trial name
- NCT00485849
- Testing
- Atomoxetine Hydrochloride
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Stress Disorders, Post-Traumatic
A Ten-Week Study Evaluating The Effectiveness And Safety Of Zoloft In Children And Adolescents With A Diagnosis Of PTSD
To evaluate the safety and efficacy of sertraline compared to placebo in children and adolescents (6 to 17 years of age) who are outpatients with Posttraumatic Stress Disorder.
- Trial name
- NCT00150306
- Testing
- Zoloft (Sertraline)
- Where
- 23 sites in United States
- Volunteers
- 160 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depressive Disorder, Anxiety Disorder
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
The objective of the study is to evaluate the pharmacokinetics of vortioxetine and its metabolites in connection with multiple oral dosing in child and adolescent patients with a DSM-IV-TR diagnosis of Depressive or Anxiety…
- Trial name
- NCT01491035
- Testing
- Vortioxetine
- Where
- 7 sites in United States, Germany
- Volunteers
- 48 people
- Sponsor
- H. Lundbeck A/S
Adolescent Well-Being, Mental Disorders, Severe
Adolescents' Well-being in Community-based Treatment Versus Residential Treatment
This is a quasi-experimental longitudinal study to compare the outcomes of youth in a Psychiatric Residential Treatment Facility (PRTF) compared to youth in the community-based Child-Focused Assertive Community Treatment Team…
- Trial name
- NCT06498427
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Outcome Referrals, Inc.
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
ADHD
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.
- Trial name
- NCT02168127
- Testing
- Drug: PRC-063, PRC-063
- Where
- 35 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Tourette Syndrome
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS.
- Trial name
- ALLEVIA2 (NCT06315751)
- Testing
- Gemlapodect
- Where
- 46 sites in United States, Belgium and 5 more
- Volunteers
- 164 people
- Sponsor
- Noema Pharma AG
Tourette Syndrome
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder
This is a two-part, randomized, multi-center, blinded study in adolescents with Tourette's Disorder. There will be an up to 21-day screening period in which subject eligibility will be determined.
- Trial name
- NCT01904773
- Where
- 7 sites in United States
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Attention Deficit Hyperactivity Disorder
Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
The purpose of this study is to evaluate the long-term safety and efficacy of ORADUR®-Methylphenidate in children and adolescents with ADHD.
- Trial name
- NCT02704390
- Testing
- ORADUR®-Methylphenidate
- Where
- 3 sites in Taiwan
- Volunteers
- 64 people
- Sponsor
- Orient Pharma Co., Ltd.
Type 1 Diabetes, T1D
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
This prospective single-arm feasibility study evaluates the Adhera Caring Digital Program for Obesity (ACDP-O), a family-centered digital health intervention designed to support adolescents and young adults with…
- Conditions
- Type 1 Diabetes, T1D, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus
- Trial name
- DASH-Obesity (NCT07638345)
- Testing
- Adhera Caring Digital Program-Obesity (ACDP-O)
- Where
- Spain
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Attention Deficit Hyperactivity Disorder (ADHD)
Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD
To provide additional, required information on the pharmacokinetic profile of SHP465 in the targeted population (children and adolescents aged 6-17 years of age with ADHD).
- Trial name
- NCT02578030
- Testing
- SHP465 12.5mg, SHP465 25mg
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Shire
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current study is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418339
- Testing
- Aripiprazole
- Where
- 39 sites in United States, Canada and 4 more
- Volunteers
- 135 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Social Anxiety Disorder
Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder…
- Trial name
- NCT00238719
- Testing
- Venlafaxine ER
- Volunteers
- 293 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Attention-Deficit/Hyperactivity Disorder
A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder
This trial was conducted to evaluate the efficacy and safety of the Centanafadine once daily (QD) extended release (XR) capsules in adolescent participants (13 - 17 years, inclusive) with attention-deficit/hyperactivity disorder…
- Trial name
- NCT05257265
- Testing
- Centanafadine Hydrochloride
- Where
- United States
- Volunteers
- 459 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette Syndrome, Tourette Syndrome in Adolescence
A Study to Explore the Effect of Sepranolone in Tourette Syndrome
The study was an open-label, randomized, multicenter, parallel, Phase 2a study in adolescents and adult patients with Tourette syndrome that aimed to explore the efficacy of Sepranolone as a treatment for Tourette syndrome, by…
- Trial name
- NCT05434546
- Testing
- Sepranolone
- Where
- 2 sites in Denmark
- Volunteers
- 26 people
- Sponsor
- Asarina Pharma
Tourette Syndrome
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
Phase 2, double-blind, placebo-controlled study to assess the safety and efficacy of NBI-98854 administered once daily (qd) for a total of 6 weeks of treatment.
- Trial name
- NCT02679079
- Testing
- NBI-98854
- Where
- 44 sites in United States
- Volunteers
- 98 people
- Sponsor
- Neurocrine Biosciences
Opioid Withdrawal (Disorder), Opioid Use Disorder
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to <18 years old abruptly discontinuing opioid use.
- Trial name
- NCT06711640
- Testing
- LUCEMYRA (lofexidine) tablets
- Where
- United States
- Sponsor
- USWM, LLC (dba US WorldMeds)
Schizophrenia, Negative Symptoms in Schizophrenia
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia
The purpose of the proposed an open label extension (OLE) study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in…
- Trial name
- NCT06067984
- Testing
- Study App
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Click Therapeutics, Inc.